Last Sunday, I preached about a blind man named Bartimaeus. The people told the blind beggar to arise and go to Jesus, who wished to see him. It dawned on me that the people surrounding the man functioned as his advocates. Upon hearing the words of Jesus, the crowd…
Search results for:
I rarely disclose my diagnosis of hemophilia B and von Willebrand disease to others. I don’t like to speak about it, which is odd for someone who writes a column on the topic. Writing is different, though. I hope it will make a difference. By sharing…
Second in a series. Read part one. A hemophilia inhibitor is like a firewall in a computer network. Clotting factor replacement therapy is supposed to enter the bloodstream and help form clots to stop bleeding, just as data should pass through a network without interruption. However, an inhibitor acts…
CSL Behring has acquired exclusive global rights to commercialize AMT-061, a potential gene therapy for hemophilia B now in a pivotal clinical trial, from its developer uniQure. Under terms of the agreement, uniQure will receive an upfront payment of $450 million from CSL Behring, and is eligible…
The U.S. Food and Drug Administration (FDA) has agreed to review Medexus Pharmaceuticals’ request to approve Ixinity (trenonacog alfa) for children with hemophilia B younger than 12. Ixinity is already approved by the FDA for adults and adolescents 12 and older. The therapy is indicated for use…
Recently, our microwave broke beyond repair, and it made me realize how much we rely on certain appliances to make life easier. In a household where hemophilia is a part of daily life, convenience isn’t just about comfort. It’s about minimizing physical strain and reducing risks. Many household chores…
My husband, Joe, and my sons, Julian and Caeleb, each have their own unofficial jobs when we decorate for the holidays. Julian brings the dusty red and green totes full of Christmas decorations in from the shed. I open them and decide what comes inside first. Joe and Caeleb…
With encouragement from the World Federation of Hemophilia (WFH) and its partners, the World Health Organization (WHO) updated its essential medicines lists to better align with international clinical guidelines for managing hemophilia and other bleeding disorders. These lists — the Essential Medicines List (EML) and the…
Preventive treatment with marzeptacog alfa activated (MarzAA) can reduce bleed frequency substantially in men with hemophilia A or B who developed inhibitors to conventional replacement therapies, according to data from a Phase 2 clinical trial. The findings were reported in the study, “Subcutaneous engineered factor…